Finance
Roche Q1 Sales up 7% on Drugs Phesgo, Vabysmo
Published by Global Banking & Finance Review®
Posted on April 24, 2025
1 min readLast updated: January 24, 2026
Add as preferred source on GoogleGlobal Banking & Finance Review®
Company
Published by Global Banking & Finance Review®
Posted on April 24, 2025
1 min readLast updated: January 24, 2026
Add as preferred source on GoogleRoche's Q1 sales rose 7% due to strong performance from drugs like Phesgo and Vabysmo, exceeding market expectations.
FRANKFURT (Reuters) -Swiss drugmaker Roche said on Thursday its first-quarter sales rose a forecast-beating 7% driven by breast cancer drug Phesgo, eye drug Vabysmo and allergy treatment Xolair.
Quarterly group revenues came in at 15.44 billion Swiss francs ($18.64 billion), slightly above average market expectations of about 15.4 billion cited by analysts.
Roche said it was still targeting an increase in full-year adjusted earnings per share at a high single-digit percentage.
(Reporting by Ludwig Burger, Editing by Rachel More)
The article discusses Roche's Q1 sales increase driven by drugs Phesgo and Vabysmo, surpassing market expectations.
What drugs contributed to Roche's sales growth? Phesgo, Vabysmo, and Xolair were key contributors.
What are Roche's future financial targets? Roche aims for high single-digit EPS growth this year.
Explore more articles in the Finance category
